A phase I, open-label, multiple dose study to assess the safety, tolerability and effect of food on pharmacokinetics of the ARRY-334543 tablet formulation given on a twice-daily oral regimen in patients with advanced solid tumors
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2013
At a glance
- Drugs Varlitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Array BioPharma
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Array BioPharma media release.
- 25 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Feb 2009 Planned end date changed from 1 Feb 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.